1. Friedrich MJ. Depression Is the Leading Cause of Disability Around the World. JAMA.

2017
Apr 18;317(15):1517.

2. Joseph P, Leong D, McKee M, Anand SS, Schwalm J-D, Teo K, et al. Reducing the Global
Burden of Cardiovascular Disease, Part 1: The Epidemiology and Risk Factors. Circ Res. 2017
Sep 1;121(6):677–94.

3. Kang H-J, Kim S-Y, Bae K-Y, Kim S-W, Shin I-S, Yoon J-S, et al. Comorbidity of depression
with physical disorders: research and clinical implications. Chonnam Med J. 2015 Apr;51(1):8–
18.

4. Dhar AK, Barton DA. Depression and the Link with Cardiovascular Disease. Front Psychiatry.
2016;7:33.

5. Fiedorowicz JG. Depression and cardiovascular disease: an update on how course of illness
may influence risk. Curr Psychiatry Rep. 2014 Oct;16(10):492.

6. Chávez-Castillo M, Martínez MS, Calvo MJ, Rojas M, Núñez V, Lameda V, et al. A Chronic
State of Systemic Stress: The Link between Depression and Cardiovascular Disease?. SM J Clin
Med. 2017;3(2):1025.

7. Gold PW, Machado-Vieira R, Pavlatou MG. Clinical and Biochemical Manifestations of

Depression: Relation to the Neurobiology of Stress. Neural Plast. 2015;2015:1–11.

8. Berk M, Williams LJ, Jacka FN, O’Neil A, Pasco JA, Moylan S, et al. So depression is an
inflammatory disease, but where does the inflammation come from?. BMC Medicine.
2013;11(1):200.

9. Lopez-Candales A, Hernández Burgos PM, Hernandez-Suarez DF, Harris D. Linking Chronic

Inflammation with Cardiovascular Disease: From Normal Aging to the Metabolic Syndrome. J
Nat Sci. 2017 Apr;3(4):pii:e341.

10. Coope A, Torsoni AS, Velloso LA. MECHANISMS IN ENDOCRINOLOGY: Metabolic and
inflammatory pathways on the pathogenesis of type 2 diabetes. Eur J Endocrinol. 2016
May;174(5):R175-187.

11. Hunter P. The inflammation theory of disease. The growing realization that chronic
inflammation is crucial in many diseases opens new avenues for treatment. EMBO Rep. 2012
Nov 6;13(11):968–70.
12. Okin D, Medzhitov R. Evolution of inflammatory diseases. Curr Biol. 2012 Sep
11;22(17):R733-740.

13. Claesson-Welsh L. Vascular permeability--the essentials. Ups J Med Sci. 2015;120(3):135–43.

14. Garn H, Bahn S, Baune BT, Binder EB, Bisgaard H, Chatila TA, et al. Current concepts in
chronic inflammatory diseases: Interactions between microbes, cellular metabolism, and
inflammation. J Allergy Clin Immunol. 2016;138(1):47–56.

15. DiSabato DJ, Quan N, Godbout JP. Neuroinflammation: the devil is in the details. J Neurochem.
2016 Oct;139 Suppl 2:136–53.

16. Polazzi E, Contestabile A. Reciprocal interactions between microglia and neurons: from
survival to neuropathology. Rev Neurosci. 2002;13(3):221–42.

17. Ling Z, Zhu Y, Tong C wai, Snyder JA, Lipton JW, Carvey PM. Progressive dopamine neuron
loss following supra-nigral lipopolysaccharide (LPS) infusion into rats exposed to LPS
prenatally. Exp Neurol. 2006 Jun;199(2):499–512.

18. Leonard BE. Inflammation and depression: a causal or coincidental link to the
pathophysiology? Acta Neuropsychiatr. 2018 Feb;30(1):1–16.

19. Buckwalter MS, Wyss-Coray T. Modelling neuroinflammatory phenotypes in vivo. J

Neuroinflammation. 2004 Jul 1;1(1):10.

20. Pasco JA, Nicholson GC, Williams LJ, Jacka FN, Henry MJ, Kotowicz MA, et al. Association
of high-sensitivity C-reactive protein with de novo major depression. Br J Psychiatry. 2010
Nov;197(5):372–7.

21. Yang C, Tiemessen KM, Bosker FJ, Wardenaar KJ, Lie J, Schoevers RA. Interleukin, tumor
necrosis factor-α and C-reactive protein profiles in melancholic and non-melancholic
depression: A systematic review. J Psychosom Res. 2018 Aug;111:58–68.

22. Hannibal KE, Bishop MD. Chronic stress, cortisol dysfunction, and pain: a
psychoneuroendocrine rationale for stress management in pain rehabilitation. Phys Ther. 2014
Dec;94(12):1816–25.

23. Slavich GM, Irwin MR. From stress to inflammation and major depressive disorder: a social
signal transduction theory of depression. Psychol Bull. 2014 May;140(3):774–815.

24. Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological

implications. Pharmacol Ther. 2011 May;130(2):226–38.
25. Stefanescu C, Ciobica A. The relevance of oxidative stress status in first episode and recurrent
depression. J Affect Disord. 2012 Dec 20;143(1–3):34–8.

26. Selley ML. Increased (E)-4-hydroxy-2-nonenal and asymmetric dimethylarginine

concentrations and decreased nitric oxide concentrations in the plasma of patients with major
depression. J Affect Disord. 2004 Jun;80(2–3):249–56.

27. Romano A, Serviddio G, Calcagnini S, Villani R, Giudetti AM, Cassano T, et al. Linking lipid
peroxidation and neuropsychiatric disorders: focus on 4-hydroxy-2-nonenal. Free Radic Biol
Med. 2017;111:281–93.

28. Leonard B, Maes M. Mechanistic explanations how cell-mediated immune activation,

inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants
play a role in the pathophysiology of unipolar depression. Neurosci Biobehav Rev. 2012
Feb;36(2):764–85.

29. Moylan S, Berk M, Dean OM, Samuni Y, Williams LJ, O’Neil A, et al. Oxidative & nitrosative
stress in depression: why so much stress? Neurosci Biobehav Rev. 2014 Sep;45:46–62.

30. Scapagnini G, Davinelli S, Drago F, De Lorenzo A, Oriani G. Antioxidants as antidepressants:

fact or fiction? CNS Drugs. 2012 Jun 1;26(6):477–90.

31. Morris G, Berk M, Klein H, Walder K, Galecki P, Maes M. Nitrosative Stress,

Hypernitrosylation, and Autoimmune Responses to Nitrosylated Proteins: New Pathways in
Neuroprogressive Disorders Including Depression and Chronic Fatigue Syndrome. Mol
Neurobiol. 2017;54(6):4271–91.

32. Rawdin BJ, Mellon SH, Dhabhar FS, Epel ES, Puterman E, Su Y, et al. Dysregulated
relationship of inflammation and oxidative stress in major depression. Brain Behav Immun.
2013 Jul;31:143–52.

33. Gloire G, Legrand-Poels S, Piette J. NF-kappaB activation by reactive oxygen species: fifteen
years later. Biochem Pharmacol. 2006 Nov 30;72(11):1493–505.

34. Siomek A. NF-κB signaling pathway and free radical impact. Acta Biochim Pol.
2012;59(3):323–31.

35. Maes M, Kubera M, Mihaylova I, Geffard M, Galecki P, Leunis J-C, et al. Increased
autoimmune responses against auto-epitopes modified by oxidative and nitrosative damage in
depression: implications for the pathways to chronic depression and neuroprogression. J Affect
Disord. 2013 Jul;149(1–3):23–9.
36. Wojda U, Salinska E, Kuznicki J. Calcium ions in neuronal degeneration. IUBMB Life. 2008
Sep;60(9):575–90.

37. Uemura T, Green M, Corson TW, Perova T, Li PP, Warsh JJ. Bcl-2 SNP rs956572 associates
with disrupted intracellular calcium homeostasis in bipolar I disorder. Bipolar Disord. 2011
Feb;13(1):41–51.

38. Guan L, Jia N, Zhao X, Zhang X, Tang G, Yang L, et al. The involvement of ERK/CREB/Bcl-2
in depression-like behavior in prenatally stressed offspring rats. Brain Res Bull. 2013 Oct;99:1–
8.

39. Morris G, Berk M. The many roads to mitochondrial dysfunction in neuroimmune and
neuropsychiatric disorders. BMC Med. 2015 Apr 1;13:68.

40. Ben-Shachar D, Karry R. Neuroanatomical pattern of mitochondrial complex I pathology varies

between schizophrenia, bipolar disorder and major depression. PLoS ONE. 2008;3(11):e3676.

41. Shao L, Martin MV, Watson SJ, Schatzberg A, Akil H, Myers RM, et al. Mitochondrial
involvement in psychiatric disorders. Ann Med. 2008;40(4):281–95.

42. Karry R, Klein E, Ben Shachar D. Mitochondrial complex I subunits expression is altered in
schizophrenia: a postmortem study. Biol Psychiatry. 2004 Apr 1;55(7):676–84.

43. Kaspar JW, Niture SK, Jaiswal AK. Nrf2:INrf2 (Keap1) signaling in oxidative stress. Free
Radic Biol Med. 2009 Nov 1;47(9):1304–9.

44. Vargas MR, Johnson DA, Sirkis DW, Messing A, Johnson JA. Nrf2 activation in astrocytes
protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J
Neurosci. 2008 Dec 10;28(50):13574–81.

45. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, et al. An Nrf2/small Maf heterodimer
mediates the induction of phase II detoxifying enzyme genes through antioxidant response
elements. Biochem Biophys Res Commun. 1997 Jul 18;236(2):313–22.

46. Stockmeier CA, Mahajan GJ, Konick LC, Overholser JC, Jurjus GJ, Meltzer HY, et al. Cellular
changes in the postmortem hippocampus in major depression. Biol Psychiatry. 2004 Nov
1;56(9):640–50.

47. Karege F, Vaudan G, Schwald M, Perroud N, La Harpe R. Neurotrophin levels in postmortem

brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain
Res Mol Brain Res. 2005 May 20;136(1–2):29–37.
48. Campbell S, MacQueen G. An update on regional brain volume differences associated with
mood disorders. Curr Opin Psychiatry. 2006 Jan;19(1):25–33.

49. Turner CA, Akil H, Watson SJ, Evans SJ. The fibroblast growth factor system and mood
disorders. Biol Psychiatry. 2006 Jun 15;59(12):1128–35.

50. Angelucci F, Brenè S, Mathé AA. BDNF in schizophrenia, depression and corresponding
animal models. Mol Psychiatry. 2005 Apr;10(4):345–52.

51. Molendijk ML, Bus B a. A, Spinhoven P, Penninx BWJH, Kenis G, Prickaerts J, et al. Serum
levels of brain-derived neurotrophic factor in major depressive disorder: state-trait issues,
clinical features and pharmacological treatment. Mol Psychiatry. 2011 Nov;16(11):1088–95.

52. Gałecki P, Talarowska M, Anderson G, Berk M, Maes M. Mechanisms underlying

neurocognitive dysfunctions in recurrent major depression. Med Sci Monit. 2015 May
27;21:1535–47.

53. Vaváková M, Ďuračková Z, Trebatická J. Markers of Oxidative Stress and Neuroprogression in

Depression Disorder. Oxid Med Cell Longev. 2015;2015:1–12.

54. Maes M, Kubera M, Obuchowiczwa E, Goehler L, Brzeszcz J. Depression’s multiple

comorbidities explained by (neuro)inflammatory and oxidative & nitrosative stress pathways.
Neuro Endocrinol Lett. 2011;32(1):7–24.

55. Aydemir O, Deveci A, Taneli F. The effect of chronic antidepressant treatment on serum brain-
derived neurotrophic factor levels in depressed patients: a preliminary study. Prog
Neuropsychopharmacol Biol Psychiatry. 2005 Feb;29(2):261–5.

56. Piccinni A, Marazziti D, Catena M, Domenici L, Del Debbio A, Bianchi C, et al. Plasma and
serum brain-derived neurotrophic factor (BDNF) in depressed patients during 1 year of
antidepressant treatments. J Affect Disord. 2008 Jan;105(1–3):279–83.

57. Gervasoni N, Aubry J-M, Bondolfi G, Osiek C, Schwald M, Bertschy G, et al. Partial
normalization of serum brain-derived neurotrophic factor in remitted patients after a major
depressive episode. Neuropsychobiology. 2005;51(4):234–8.

58. Lugo-Huitrón R, Ugalde Muñiz P, Pineda B, Pedraza-Chaverrí J, Ríos C, Pérez-de la Cruz V.

Quinolinic Acid: An Endogenous Neurotoxin with Multiple Targets. Oxid Med Cell Longev.
2013;2013:1–14.

59. Maes M, Mihaylova I, Ruyter MD, Kubera M, Bosmans E. The immune effects of TRYCATs
(tryptophan catabolites along the IDO pathway): relevance for depression - and other conditions
 characterized by tryptophan depletion induced by inflammation. Neuro Endocrinol Lett. 2007
Dec;28(6):826–31.

60. Maes M, Leonard BE, Myint AM, Kubera M, Verkerk R. The new “5-HT” hypothesis of
depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which
leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan
catabolites (TRYCATs), both of which contribute to the onset of depression. Prog
Neuropsychopharmacol Biol Psychiatry. 2011 Apr 29;35(3):702–21.

61. Wichers MC, Koek GH, Robaeys G, Verkerk R, Scharpé S, Maes M. IDO and interferon-alpha-
induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity.
Mol Psychiatry. 2005 Jun;10(6):538–44.

62. Paz-Filho G, Licinio J, Wong M-L. Pathophysiological basis of cardiovascular disease and
depression: a chicken-and-egg dilemma. Rev Bras Psiquiatr. 2010 Jun;32(2):181–91.

63. Lopez-Vilchez I, Diaz-Ricart M, Navarro V, Torramade S, Zamorano-Leon J, Lopez-Farre A, et

al. Endothelial damage in major depression patients is modulated by SSRI treatment, as
demonstrated by circulating biomarkers and an in vitro cell model. Transl Psychiatry. 2016
06;6(9):e886.

64. Felice F, Di Stefano R, Pini S, Mazzotta G, Bovenzi FM, Bertoli D, et al. Influence of
depression and anxiety on circulating endothelial progenitor cells in patients with acute
coronary syndromes. Hum Psychopharmacol. 2015 May;30(3):183–8.

65. Van Sloten TT, Schram MT, Adriaanse MC, Dekker JM, Nijpels G, Teerlink T, et al. Endothelial
dysfunction is associated with a greater depressive symptom score in a general elderly
population: the Hoorn Study. Psychol Med. 2014 May;44(7):1403–16.

66. Dimopoulos N, Piperi C, Salonicioti A, Mitsonis C, Liappas I, Lea RW, et al. Elevation of
plasma concentration of adhesion molecules in late-life depression. Int J Geriatr Psychiatry.
2006 Oct;21(10):965–71.

67. Van Dooren FEP, Schram MT, Schalkwijk CG, Stehouwer CDA, Henry RMA, Dagnelie PC, et
al. Associations of low grade inflammation and endothelial dysfunction with depression - The
Maastricht Study. Brain Behav Immun. 2016 Aug;56:390–6.

68. Wallerath T, Witte K, Schäfer SC, Schwarz PM, Prellwitz W, Wohlfart P, et al. Down-regulation
of the expression of endothelial NO synthase is likely to contribute to glucocorticoid-mediated
hypertension. Proc Natl Acad Sci USA. 1999 Nov 9;96(23):13357–62.
69. Wilbert-Lampen U, Straube F, Trapp A, Deutschmann A, Plasse A, Steinbeck G. Effects of
corticotropin-releasing hormone (CRH) on monocyte function, mediated by CRH-receptor
subtype R1 and R2: a potential link between mood disorders and endothelial dysfunction? J
Cardiovasc Pharmacol. 2006 Jan;47(1):110–6.

70. Bruno RL, Myers SJ, Glassman AH. A correlational study of cardiovascular autonomic
functioning and unipolar depression. Biol Psychiatry. 1983 Feb;18(2):227–35.

71. Scalco AZ, Scalco MZ, Azul JBS, Lotufo Neto F. Hypertension and depression. Clinics. 2005
Jun;60(3):241–50.

72. Halperin D, Reber G. Influence of antidepressants on hemostasis. Dialogues Clin Neurosci.

2007;9(1):47–59.

73. Serebruany VL, Glassman AH, Malinin AI, Sane DC, Finkel MS, Krishnan RR, et al. Enhanced
platelet/endothelial activation in depressed patients with acute coronary syndromes: evidence
from recent clinical trials. Blood Coagul Fibrinolysis. 2003 Sep;14(6):563–7.

74. Gehi A, Musselman D, Otte C, Bruce Royster E, Ali S, Whooley MA. Depression and platelet
activation in outpatients with stable coronary heart disease: findings from the Heart and Soul
Study. Psychiatry Res. 2010 Feb 28;175(3):200–4.

75. Bloomgarden ZT. World congress on insulin resistance, diabetes, and cardiovascular disease:
Part 1. Diabetes Care. 2011 Jul;34(7):e115-120.

76. Draznin B. Molecular mechanisms of insulin resistance: serine phosphorylation of insulin

receptor substrate-1 and increased expression of p85alpha: the two sides of a coin. Diabetes.
2006 Aug;55(8):2392–7.

77. Snel M, Jonker JT, Schoones J, Lamb H, de Roos A, Pijl H, et al. Ectopic Fat and Insulin
Resistance: Pathophysiology and Effect of Diet and Lifestyle Interventions. Int J Endocrinol.
2012;2012:1–18.

78. Austin AW, Gordon JL, Lavoie KL, Arsenault A, Dasgupta K, Bacon SL. Differential
association of insulin resistance with cognitive and somatic symptoms of depression. Diabet
Med. 2014 Aug;31(8):994–1000.

79. McCracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome. Clin

Dermatol. 2018 Feb;36(1):14–20.
80. Webb M, Davies M, Ashra N, Bodicoat D, Brady E, Webb D, et al. The association between
depressive symptoms and insulin resistance, inflammation and adiposity in men and women.
PLoS ONE. 2017;12(11):e0187448.

81. Mancuso P. The role of adipokines in chronic inflammation. Immunotargets Ther. 2016;5:47–
56.

82. Sáinz N, Barrenetxe J, Moreno-Aliaga MJ, Martínez JA. Leptin resistance and diet-induced
obesity: central and peripheral actions of leptin. Metab Clin Exp. 2015 Jan;64(1):35–46.

83. Cimmino MA, Andraghetti G, Briatore L, Salani B, Parodi M, Cutolo M, et al. Changes in
adiponectin and leptin concentrations during glucocorticoid treatment: a pilot study in patients
with polymyalgia rheumatica. Ann N Y Acad Sci. 2010 Apr;1193:160–3.

84. Agrawal S, Gollapudi S, Su H, Gupta S. Leptin activates human B cells to secrete TNF-α, IL-6,
and IL-10 via JAK2/STAT3 and p38MAPK/ERK1/2 signaling pathway. J Clin Immunol. 2011
Jun;31(3):472–8.

85. Taylor VH, MacQueen GM. The Role of Adipokines in Understanding the Associations
between Obesity and Depression. J Obes. 2010;2010:1–6.

86. Sukumaran S, Dubois DC, Jusko WJ, Almon RR. Glucocorticoid effects on adiponectin
expression. Vitam Horm. 2012;90:163–86.

87. Milaneschi Y, Lamers F, Bot M, Drent ML, Penninx BWJH. Leptin Dysregulation Is
Specifically Associated With Major Depression With Atypical Features: Evidence for a
Mechanism Connecting Obesity and Depression. Biol Psychiatry. 2017 01;81(9):807–14.

88. Carvalho AF, Rocha DQC, McIntyre RS, Mesquita LM, Köhler CA, Hyphantis TN, et al.
Adipokines as emerging depression biomarkers: a systematic review and meta-analysis. J
Psychiatr Res. 2014 Dec;59:28–37.

89. Machado-Vieira R, Gold PW, Luckenbaugh DA, Ballard ED, Richards EM, Henter ID, et al.
The role of adipokines in the rapid antidepressant effects of ketamine. Mol Psychiatry.
2017;22(1):127–33.